Every year at The Liver Meeting®, AASLD recognizes deserving colleagues for their accomplishments and contributions to the liver community through our Distinguished Awards. These are AASLD’s most prestigious awards. Congratulations to the 2024 Distinguished Awardees!
The Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories — recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.
Asish C. Misra, Juliet Emamaullee – 15 May 2022 – The evaluation of a liver transplantation candidate is a complex and detailed process that in many cases must be done in an expedited manner because of the critically ill status of some patients with end‐stage liver disease. It involves great effort from and the collaboration of multiple disciplines, and during the evaluation several studies and interventions are performed to assess and potentially prepare a patient for liver transplant. Here we review the liver transplantation evaluation from a surgical perspective.
Amanda Cheung, Josh Levitsky – 15 May 2022
Søren Møller, Jens D. Hove – 15 May 2022
Jason J. Pan, Robert J. Fontana – 15 May 2022
Amanda Cheung, Josh Levitsky – 15 May 2022
Jason J. Pan, Robert J. Fontana – 15 May 2022
Asish C. Misra, Juliet Emamaullee – 15 May 2022 – The evaluation of a liver transplantation candidate is a complex and detailed process that in many cases must be done in an expedited manner because of the critically ill status of some patients with end‐stage liver disease. It involves great effort from and the collaboration of multiple disciplines, and during the evaluation several studies and interventions are performed to assess and potentially prepare a patient for liver transplant. Here we review the liver transplantation evaluation from a surgical perspective.
Masato Yoneda, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, Masataka Taguri, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima – 15 May 2022 – The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes. This trial follows up on our previous work and forms part of the ToPiND study. We aimed to combine tofogliflozin and pioglitazone treatment for hepatic steatosis in patients with NAFLD and T2DM.